Premium
Bupropion‐SR in treatment of social phobia
Author(s) -
Emmanuel Naresh P.,
BrawmanMintzer Olga,
Morton W. Alexander,
Book Sarah W.,
Johnson Michael R.,
Lorberbaum Jeffrey P.,
Ballenger James C.,
Lydiard R. Bruce
Publication year - 2000
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/1520-6394(2000)12:2<111::aid-da9>3.0.co;2-3
Subject(s) - bupropion , clinical global impression , psychology , dosing , rating scale , open label , clinical trial , psychiatry , clinical psychology , medicine , alternative medicine , developmental psychology , pathology , smoking cessation , placebo
A 12‐week, open label flexible dosing study was conducted to evaluate the efficacy of bupropion‐SR in the treatment of generalized social phobia. The primary outcome measures include the Clinical Global Impression of Improvement (CGI‐I) and the Brief Social Phobia Rating Scale (BSPS). A total of 18 subjects were enrolled. Five of the ten subjects who completed all 12 weeks were considered as responders. Response to treatment was defined as a CGI‐I score of 1 or 2, (“much improved” or “very much improved,” respectively) and a >50% decrease in BSPS score. The final doses for the completers ranged between 200 and 400 mg/day (mean 366±68 mg/day). The medication was generally well tolerated. Findings from this open‐label trial suggest that bupropion‐SR may be useful in treating generalized social phobia. Depression and Anxiety 12:111–113, 2000. © 2000 Wiley‐Liss, Inc.